» Articles » PMID: 38264503

Jaundice-predominant Manifestation of Kawasaki Disease in Children

Overview
Journal Front Pediatr
Specialty Pediatrics
Date 2024 Jan 24
PMID 38264503
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A jaundice-predominant presentation of Kawasaki disease (KD) is atypical.

Methods: A total of 12 children with KD with a predominant manifestation of jaundice at MacKay Children's Hospital were reviewed, along with 42 cases reported in the literature since 1990.

Results: The median age of the 12 patients was 1.85 years (range: 3 months-4 years), and 66.6% were male. All of the patients had elevated liver function at presentation, 50% had hydrops of the gallbladder, and almost 60% had gastrointestinal symptoms and signs. Complete KD was evident in 11 of the 12 patients (91.7%), and two patients (16.7%) had recurrent episodes. All of the patients received intravenous immunoglobulin (IVIG); however, one-third were refractory to treatment. Corticosteroids were used in five (41.7%) of the patients. Three (25%) of the patients had shock, and seven (58.3%) had coronary artery abnormalities, of whom one (8.3%) had persistent coronary artery aneurysm and the others recovered. A review of the 42 cases in the literature showed that the children with a jaundice-predominant presentation of KD had high rates of IVIG-refractory disease (25%), coronary artery abnormalities (25%), shock (13.2%), and corticosteroid treatment (24.2%).

Conclusions: Children with KD presenting with a jaundice-predominant manifestation are at a higher risk of IVIG-refractory disease, coronary artery abnormalities, and more recurrent episodes. Physicians should be aware of the risk of shock in this population.

Citing Articles

Unraveling the gut: the pivotal role of intestinal mechanisms in Kawasaki disease pathogenesis.

Tao E, Lang D Front Immunol. 2024; 15():1496293.

PMID: 39664384 PMC: 11633670. DOI: 10.3389/fimmu.2024.1496293.

References
1.
Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K . Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2006; 166(2):131-7. DOI: 10.1007/s00431-006-0223-z. View

2.
Dimitriades V, Brown A, Gedalia A . Kawasaki disease: pathophysiology, clinical manifestations, and management. Curr Rheumatol Rep. 2014; 16(6):423. DOI: 10.1007/s11926-014-0423-x. View

3.
Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T . Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006; 113(22):2606-12. DOI: 10.1161/CIRCULATIONAHA.105.592865. View

4.
Luzzatto C, Zancan L, Guglielmi M . Obstructive jaundice in Kawasaki's disease. Z Kinderchir. 1990; 45(1):50-1. DOI: 10.1055/s-2008-1042550. View

5.
Falcini F, Resti M, Azzari C, Simonini G, Veltroni M, Lionetti P . Acute febrile cholestasis as an inaugural manifestation of Kawasaki's disease. Clin Exp Rheumatol. 2001; 18(6):779-80. View